Cargando…

Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience

SIMPLE SUMMARY: The advent of immune-checkpoint inhibitors (ICIs) has significantly changed the management of patients with non-small cell lung cancer (NSCLC). Although the assessment of PD-L1 expression remains the gold standard for the selection of cases for immunotherapy, previous experiments hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monaco, Lavinia, Gemelli, Maria, Gotuzzo, Irene, Bauckneht, Matteo, Crivellaro, Cinzia, Genova, Carlo, Cortinovis, Diego, Zullo, Lodovica, Ammoni, Luca Carlofrancesco, Bernasconi, Davide Paolo, Rossi, Giovanni, Morbelli, Silvia, Guerra, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037395/ https://www.ncbi.nlm.nih.gov/pubmed/33915801 http://dx.doi.org/10.3390/cancers13071634

Ejemplares similares

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
por: Cordani, Nicoletta, et al.
Publicado: (2023)

Prognostic value of immunotherapy-induced organ inflammation assessed on (18)FDG PET in patients with metastatic non-small cell lung cancer
por: Humbert, Olivier, et al.
Publicado: (2022)

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
por: Rossi, Giovanni, et al.
Publicado: (2020)

Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?
por: Tanda, Enrica Teresa, et al.
Publicado: (2021)

The heterogeneity of lung perfusion patterns in SPECT/CT during COVID-19: not only embolism
por: Monaco, Lavinia, et al.
Publicado: (2021)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics
por: Barabino, Emanuele, et al.
Publicado: (2022)

Respiratory Gating and the Performance of PET/CT in Pulmonary Lesions
por: Crivellaro, Cinzia, et al.
Publicado: (2020)

Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology
por: Donegani, Maria Isabella, et al.
Publicado: (2020)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
por: Bauckneht, Matteo, et al.
Publicado: (2017)

Budget Impact di afatinib per il trattamento in prima linea del Non Small Cell Lung Cancer (NSCLC) con mutazioni non comuni EGFR
por: Pompilio, Giuseppe, et al.
Publicado: (2022)

Focal bone lesions in hiv-positive patient treated with tenofovir
por: Mangioni, Davide, et al.
Publicado: (2014)

2-[(18)F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study
por: Gay, Stefano, et al.
Publicado: (2022)

Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers
por: Bauckneht, Matteo, et al.
Publicado: (2019)

Potential application of cryobiopsy for histo-molecular characterization of mediastinal lymph nodes in patients with thoracic malignancies: a case presentation series and implications for future developments
por: Genova, Carlo, et al.
Publicado: (2022)

Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
por: Putzu, Carlo, et al.
Publicado: (2023)

Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC
por: Rossi, Alessandro, et al.
Publicado: (2021)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
por: Gemelli, Maria, et al.
Publicado: (2022)

Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center
por: Vallome, Giacomo, et al.
Publicado: (2023)

Beyond Covid-19 vaccination-associated pitfalls on [(18)F]Fluorodeoxyglucose (FDG) PET: a case of a concomitant sarcoidosis
por: Bauckneht, Matteo, et al.
Publicado: (2021)

(123)I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies
por: Pardini, Matteo, et al.
Publicado: (2020)

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Immunotherapy in NSCLC Patients with Brain Metastases
por: Buriolla, Silvia, et al.
Publicado: (2022)

Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy
por: Zarogoulidis, Paul, et al.
Publicado: (2022)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Maintenance therapy in NSCLC: why? To whom? Which agent?
por: Novello, Silvia, et al.
Publicado: (2011)

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
por: Cortellini, Alessio, et al.
Publicado: (2021)

New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer
por: Villa, Matteo, et al.
Publicado: (2021)

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
por: Castello, Angelo, et al.
Publicado: (2020)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?
por: Zarogoulidis, Paul, et al.
Publicado: (2020)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
por: Roller, John F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ru750ql3jgash82dc2r5qagn24